Xtant Medical beats top-line and bottom-line estimates; raises FY25 outlook

4 hours ago 1

Xtant Medical press release (NYSE:XTNT): Q2 GAAP EPS of $0.02 beats by $0.03.
Revenue of $35.4M (+18.4% Y/Y) beats by $4.05M.
Adjusted EBITDA of $6.9 million compared to Adjusted EBITDA loss of $0.6 million in the prior year quarter.
Cash

Recommended For You